About Us
Asia Air WatchLive PM2.5 Medical Alerts
Research Watch
•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs•स्क्रिनमा देखिने चुरोट: सुर्तीजन्य हानि न्यूनीकरण नीतिमा दक्षिण एसियाले अझै के छुटाइरहेको छ•नेपालमा पिसाब नलीको संक्रमण र एन्टिबायोटिक प्रतिरोधको बढ्दो संकट•Frontline Perspectives on Nursing Leadership in Nepal•Protecting the Smallest Lungs from the Hidden Grip of RSV in Kathmandu•The Heavy Burden of Bullying on Student Wellbeing in Nepal•The Emerging Landscape of Thyroid Health in Central Nepal•How a Recent Western Nepal Study is Redefining Anemia Diagnosis•How H. Pylori is Impacting the Health of Karnali’s High-Altitude Communities•Sweet Poison, Bitter Reality: The Unseen Diabetes Epidemic Among Nepal’s Youth•How Missing Checklists and Protocols are Costing Lives in Nepal’s ERs

The American Society of Clinical Psychopharmacology Task Force Consensus Statement on Combination Psychopharmacology.

Researchers

Joseph F Goldberg, Gin S Malhi, Manish K Jha, A John Rush, Rajnish Mago, Anita H Clayton, Leslie Citrome, Holly A Swartz, Marlene P Freeman, Michael Berk, Siegfried Kasper, Roger S McIntyre, Sheldon H Preskorn, Andrea Fagiolini, Dan V Iosifescu, M Lynn Crismon, Lawrence J Cohen, S Nassir Ghaemi, John S Markowitz, Taeho Greg Rhee, Eduard Vieta, Henry A Nasrallah, Christoph U Correll, Chittaranjan Andrade, Michael E Thase, Mauricio Tohen, Matthew Macaluso, Richard C Shelton, Charles B Nemeroff, Carlos A Zarate, Michael J Gitlin, Lars V Kessing, Beny Lafer, Allan H Young, Stephen M Stahl, Ralph Kupka, Konstantinos N Fountoulakis, Robert M Post, David L Dunner, Adele C Viguera, Deanna L Kelly, Lakshmi N Yatham, Joshua D Rosenblat, Scott T Aaronson, Mark A Frye, John R Geddes, Guy M Goodwin, Suzanne C Harris, Philip Gorwood, David S Baldwin, Andrew A Nierenberg, John M Kane, Michael J Ostacher, Martin Alda, Anthony J Rothschild, Alessandro Serretti, Andreas Reif, James W Murrough, Steven C Stoner, Siu Wa Tang, Shih-Ku Lin

Abstract

<b>Objective:</b> Combination psychopharmacology is common but understudied. Expert guidance is needed to help practitioners follow rationale-based principles when devising and maintaining polydrug regimens. <b>Participants:</b> The American Society of Clinical Psychopharmacology (ASCP) convened an expert Task Force composed of 60 academic clinical psychiatrists and psychiatric pharmacists from 16 countries. Members developed and completed a 2-round Delphi survey on the use of combination psychopharmacology. <b>Evidence:</b> Survey content focused on experts' opinions regarding pharmacokinetic and pharmacodynamic interactions, efficacy vs tolerability risk-benefit analyses, and clinical decision-making. Gaps were identified between evidence-based literature, personal experience, and pharmacologic rationales. <b>Consensus Process:</b> Consensus (defined as &#x2265;75% agreement [or disagreement] with "strong" or "moderate" ratings) was achieved on 62/66 items (94%). Findings encompassed several principles: (1) General: (<i>a</i>) reserve combination psychopharmacology for complex, comorbidly ill, treatment-resistant presentations; (<i>b</i>) favor complementary/nonredundant drug mechanisms; (<i>c</i>) recognize drug-drug interactions; (<i>d</i>) focus on the mechanistic <i>coherence</i> of polydrug regimens rather than sheer number of components; (<i>e</i>) proactively address cumulative adverse effects; (<i>f</i>) prioritize patient preference via shared decision-making. (2) Specific: (<i>a</i>) avoid nonclozapine antipsychotic combinations; (<i>b</i>) favor switching over augmenting after minimal improvement. (3) Strategic: (<i>a</i>) before augmenting, assure/update diagnoses, dose optimization, adherence, and alignment to therapeutic targets; (<i>b</i>) individualized decisions should govern sequential versus simultaneous pharmacotherapies for comorbidities; (<i>c</i>) consider when adjunctive psychotherapies are preferable to polypharmacotherapies. <b>Conclusions:</b> In the context of limited research, the consensus recommendations from this Task Force can help practitioners identify clinically driven principles that shape coherent multidrug regimens and identify issues in need of further empirical investigation.
Source: PubMed (PMID: 43055664)View Original on PubMed